Cardiff Oncology, Inc. - Common Stock (CRDF) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRDF on Nasdaq
Shares outstanding
66,577,393
Price per share
$2.81
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
25,150,264
Total reported value
$51,811,088
% of total 13F portfolios
0%
Share change
-3,461,907
Value change
-$9,699,944
Number of holders
109
Price from insider filings
$2.81
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cardiff Oncology, Inc. - Common Stock (CRDF) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 5.8% +38% $9,141,811 +$2,380,447 3,841,097 +35% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.6% $10,141,068 3,728,334 The Vanguard Group 30 Jun 2025
PFIZER INC 3.6% $5,739,548 2,411,575 Pfizer Inc. 13-5315170 31 Dec 2024

As of 30 Sep 2025, 109 institutional investors reported holding 25,150,264 shares of Cardiff Oncology, Inc. - Common Stock (CRDF). This represents 38% of the company’s total 66,577,393 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cardiff Oncology, Inc. - Common Stock (CRDF) together control 35% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6% 3,985,536 +1.2% 0% $8,210,204
VANGUARD GROUP INC 5.4% 3,588,933 -3.7% 0% $7,393,202
Laurion Capital Management LP 3.7% 2,465,872 +37% 0.69% $5,079,696
Pfizer Inc 3.6% 2,411,575 0% 1.1% $4,967,845
BLAIR WILLIAM & CO/IL 3.3% 2,213,606 -12% 0.01% $4,560,028
ACORN CAPITAL ADVISORS, LLC 2.9% 1,962,084 +39% 2.1% $4,041,893
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,543,320 +3% 0% $3,180,068
STATE STREET CORP 1.7% 1,146,359 +1.8% 0% $2,361,500
FLPUTNAM INVESTMENT MANAGEMENT CO 0.9% 597,233 +1009% 0.02% $1,230,300
NORTHERN TRUST CORP 0.78% 519,752 -28% 0% $1,070,690
GOLDMAN SACHS GROUP INC 0.68% 454,726 +496% 0% $936,736
Bank of New York Mellon Corp 0.52% 347,485 +4.1% 0% $715,819
MORGAN STANLEY 0.47% 310,659 -61% 0% $639,958
NATIONAL BANK OF CANADA /FI/ 0.31% 208,700 +652088% 0% $429,922
UBS Group AG 0.31% 206,175 +4.4% 0% $424,721
TWO SIGMA INVESTMENTS, LP 0.31% 204,010 -54% 0% $420,261
Nuveen, LLC 0.29% 194,310 -65% 0% $400,279
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.28% 189,315 0% 0% $389,989
JANE STREET GROUP, LLC 0.24% 161,928 0% $333,572
XTX Topco Ltd 0.23% 156,161 +20% 0.02% $321,692
Avestar Capital, LLC 0.21% 140,469 0% 0.02% $289,366
ROYAL BANK OF CANADA 0.17% 116,405 -39% 0% $241,000
AlphaCore Capital LLC 0.17% 109,926 +8.2% 0.01% $226,448
RENAISSANCE TECHNOLOGIES LLC 0.15% 101,800 -22% 0% $209,708
Cubist Systematic Strategies, LLC 0.13% 88,903 0% $183,140

Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 117,468 $329,692 +$45,568 $2.81 5
2025 Q3 25,150,264 $51,811,088 -$9,699,944 $2.06 109
2025 Q2 28,660,334 $90,269,224 -$11,262,617 $3.15 114
2025 Q1 32,345,011 $101,559,591 +$10,196,279 $3.14 116
2024 Q4 28,092,578 $121,917,438 +$50,159,876 $4.34 117
2024 Q3 12,761,449 $34,075,026 -$900,038 $2.67 83
2024 Q2 12,794,219 $28,397,554 +$5,434,902 $2.22 89
2024 Q1 8,576,486 $45,797,587 +$17,619,137 $5.34 75
2023 Q4 5,280,075 $7,814,926 -$209,486 $1.48 53
2023 Q3 5,422,916 $7,537,555 -$761,483 $1.39 55
2023 Q2 5,961,928 $8,764,511 -$1,396,407 $1.47 48
2023 Q1 7,034,521 $11,608,581 -$750,291 $1.65 50
2022 Q4 7,684,112 $10,755,201 -$321,468 $1.40 53
2022 Q3 7,923,892 $12,204,032 -$1,958,723 $1.54 48
2022 Q2 7,862,248 $17,298,792 -$14,116,920 $2.20 49
2022 Q1 13,784,654 $34,159,207 -$29,172,144 $2.48 78
2021 Q4 21,414,814 $128,453,136 +$2,410,627 $6.01 78
2021 Q3 21,013,586 $140,007,888 -$33,563,840 $6.66 84
2021 Q2 26,365,931 $175,332,000 +$10,071,177 $6.65 83
2021 Q1 24,079,480 $222,964,000 -$73,062,531 $9.26 69
2020 Q4 25,674,887 $461,841,000 +$144,054,588 $17.99 74
2020 Q3 18,710,137 $265,494,000 +$207,896,302 $14.19 61
2020 Q2 4,923,520 $24,668,000 +$24,667,956 $5.01 22